IBD Evidence

Simptomi

Život sa IBD: umor, bol i dijelovi koje niko ne mjeri

Remisija na papiru i remisija kao iskustvo su različite stvari, a razlika je mjesto gdje većina tereta leži.

Ažurirano 2 min čitanja 22 citati Snaga dokaza 3/5

Umor

Umor je jedan od najčešće prijavljivanih simptoma u IBD-u i među najmanje često tretiranim. Održava se u velikom dijelu ljudi čija je upala kontrolisana, što znači da nije samo marker aktivnosti bolesti.

Doprinosi uključuju anemiju (nedostatak željeza je vrlo čest i ispravljiv), poremećaj sna, efekte lijekova, hroničnu upalu i psihološki teret nepredvidive bolesti. Ispravni uzroci su vrijedni eksplicitnog rješavanja, jer ih niko neće spomenuti na petnaestominutnom sastanku fokusiranom na kalprotectin.

Teret umora u IBD-u

Mentalno zdravlje

Stope anksioznosti i depresije u IBD-u znatno premašuju osnovne stope. Očigledno objašnjenje — život s nepredvidivom, stigmatiziranom, ponekad inkontinencijom uzrokovanom bolešću je stresan — je stvarno i vjerovatno nije cijela priča, s obzirom na upalne i crijevno-mozgane puteve pokrivene na našoj stranici o dokazima crijevno-mozgane osi.

Ono što je praktično važno je da je ovo tretabilno i rutinski propušteno. Psihološka podrška je dio njege IBD-a u evropskim smjernicama i nerazmjerno se pruža.

Praktični teret

  • Anksioznost zbog pristupa toaletu, koja ograničava putovanja, rad i društveni život više nego što kliničari obično cijene.
  • Nepredvidivost. Planiranje je teško kada iznenada može doći do pogoršanja.
  • Upravljanje dijetom. Individualni okidači, bez validirane liste, i mnogo kontradiktornih savjeta — vidi dijetu.
  • Zapošljavanje. Umor i hitnost loše se uklapaju u krute radne obrasce.
  • Putovanje. Skladištenje lijekova, sigurnost hrane i pristup — pokriveno na našoj stranici o zdravstvenom putovanju.

Epidemiologija

Incidencija IBD-a je visoka i stabilna u Evropi i Sjevernoj Americi i naglo raste u novim industrijaliziranim zemljama. Taj geografski obrazac je jedan od najjačih argumenata za ekološku komponentu — dijeta, higijena, antibiotici i mikrobiom su svi kandidati, a nijedan nije utvrđen.

Česta pitanja

Zašto sam iscrpljen ako sam u remisiji?
Umor često opstaje nakon kontrole upale. Provjerite feritin i B12 prvo; oni su česti, ispravni i često propušteni.
Da li stres uzrokuje moja pogoršanja?
Stres vjerovatno utiče na simptome, a dokazi da uzrokuje upalu su slabiji od narodnog modela. Nije vaša krivica.
Hoću li trebati operaciju?
Značajna manjina to čini, a proporcija je opala kako je efikasna terapija došla ranije — vidi tretman.
Mogu li putovati?
Da, uz planiranje oko lijekova, osiguranja i sigurnosti hrane.

Reference

Svaka citacija u nastavku povezuje na izvorni recenzirani zapis na PubMed-u ili putem DOI-a. Ništa ovdje nije zamjena za medicinski savjet.

  1. Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization Assa A, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40528309
  2. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation Wine E, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40677018Full text
  3. Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and heterogeneity patterns Steinmann M, Lampe D, Grosser J, et al. · Infection · 2024 · Meta-analysis DOIPubMed 38236326Full text
  4. Acute severe ulcerative colitis trials: the past, the present and the future Honap S, Jairath V, Sands BE, et al. · Gut · 2024 · Systematic review DOIPubMed 38834296Full text
  5. Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses Buie MJ, Quan J, Windsor JW, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023 · Meta-analysis DOIPubMed 35863682
  6. Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease Valvano M, Capannolo A, Cesaro N, et al. · Nutrients · 2023 · Systematic review DOIPubMed 37686856Full text
  7. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review Kuenzig ME, Fung SG, Marderfeld L, et al. · Gastroenterology · 2022 · Systematic review DOIPubMed 34995526
  8. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis Barberio B, Zamani M, Black CJ, et al. · The lancet. Gastroenterology & hepatology · 2021 · Meta-analysis DOIPubMed 33721557
  9. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD Turner D, Ricciuto A, Lewis A, et al. · Gastroenterology · 2021 · Systematic review DOIPubMed 33359090
  10. ACG Clinical Guideline: Management of Irritable Bowel Syndrome Lacy BE, Pimentel M, Brenner DM, et al. · The American journal of gastroenterology · 2021 · Clinical guideline DOIPubMed 33315591
  11. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies Ng SC, Shi HY, Hamidi N, et al. · Lancet (London, England) · 2017 · Systematic review DOIPubMed 29050646
  12. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target Peyrin-Biroulet L, Sandborn W, Sands BE, et al. · The American journal of gastroenterology · 2015 · Systematic review DOIPubMed 26303131
  13. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study Ferrante M, D'Haens G, Jairath V, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39581202
  14. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial Cox SR, Lindsay JO, Fromentin S, et al. · Gastroenterology · 2020 · Randomised controlled trial DOIPubMed 31586453
  15. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. · The New England journal of medicine · 2019 · Randomised controlled trial DOIPubMed 31553834
  16. Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies Caron B, Honap S, Peyrin-Biroulet L · Journal of Crohn's & colitis · 2024 · Review DOIPubMed 39475082Full text
  17. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life Nguyen TV, Damiani G, Orenstein LAV, et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · 2021 · Review DOIPubMed 32460374
  18. Iron Deficiency Anemia in Inflammatory Bowel Diseases-A Narrative Review Mahadea D, Adamczewska E, Ratajczak AE, et al. · Nutrients · 2021 · Review DOIPubMed 34836263Full text
  19. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities Elmets CA, Leonardi CL, Davis DMR, et al. · Journal of the American Academy of Dermatology · 2019 · Review DOIPubMed 30772097
  20. Fatigue in inflammatory bowel disease Grimstad T, Norheim KB · Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke · 2016 · Review DOIPubMed 27830906
  21. Global evolution of inflammatory bowel disease across epidemiologic stages Hracs L, Windsor JW, Gorospe J, et al. · Nature · 2025 · Journal article DOIPubMed 40307548Full text
  22. Psychological symptoms and quality of life in patients with inflammatory bowel disease in China: A multicenter study Zhang J, Liu C, An P, et al. · United European gastroenterology journal · 2024 · Journal article DOIPubMed 38315582Full text

Ova stranica je automatski prevedena sa engleskog. Citati i brojevi su nepromijenjeni. Pročitajte engleski original ako nešto zvuči čudno. Pročitajte engleski original